NICE confirms rejection of Gen-Probe and Progenika hypercholesterolaemia tests
This article was originally published in Clinica
Executive Summary
Molecular diagnostics companies Gen-Probe and Progenika were dealt a blow by the UK’s National Institute for Health and Clinical Excellence (NICE) when the latter published final guidance recommending against routine use of Gen-Probe’s Elucigene FH20 and Progenika’s LIPOchip for either confirmation or cascade screening of familial hypercholesterolaemia (FH).